ImpediMed Limited Stock

Equities

IPD

AU000000IPD8

Advanced Medical Equipment & Technology

Market Closed - Australian S.E. 02:10:52 2024-04-24 am EDT 5-day change 1st Jan Change
0.09 AUD 0.00% Intraday chart for ImpediMed Limited -4.26% -37.93%
Sales 2024 * 10.87M 7.05M Sales 2025 * 19.14M 12.42M Capitalization 182M 118M
Net income 2024 * -21M -13.63M Net income 2025 * -14M -9.09M EV / Sales 2024 * 14.5 x
Net cash position 2024 * 24.71M 16.03M Net cash position 2025 * 13.87M 9M EV / Sales 2025 * 8.79 x
P/E ratio 2024 *
-9.42 x
P/E ratio 2025 *
-14.8 x
Employees 76
Yield 2024 *
-
Yield 2025 *
-
Free-Float 85.74%
More Fundamentals * Assessed data
Dynamic Chart
1 week-4.26%
Current month-2.17%
1 month+2.27%
3 months-33.33%
6 months-30.77%
Current year-37.93%
More quotes
1 week
0.09
Extreme 0.09
0.10
1 month
0.09
Extreme 0.085
0.11
Current year
0.08
Extreme 0.076
0.16
1 year
0.08
Extreme 0.076
0.24
3 years
0.05
Extreme 0.049
0.24
5 years
0.03
Extreme 0.032
0.35
10 years
0.03
Extreme 0.032
1.82
More quotes
Managers TitleAgeSince
Chief Executive Officer - Jan. 07
Director of Finance/CFO - 23-09-27
Chief Tech/Sci/R&D Officer - 23-09-25
Members of the board TitleAgeSince
Chief Executive Officer - Jan. 07
Director of Finance/CFO - 23-09-27
Chairman - 23-09-27
More insiders
Date Price Change Volume
24-04-24 0.09 0.00% 900,191
24-04-23 0.09 0.00% 639,897
24-04-22 0.09 -3.23% 808,812
24-04-19 0.093 -2.11% 1,210,425
24-04-18 0.095 +1.06% 1,334,047

Delayed Quote Australian S.E., April 24, 2024 at 02:10 am EDT

More quotes
ImpediMed Limited is an Australia-based medical software technology company. The Company is engaged in the development, manufacture, and sale of bioimpedance spectroscopy (BIS) systems and software services with a focus on the early detection of lymphoedema and heart failure. It measures, monitors and manages fluid status and tissue composition using BIS. The Company’s SOZO digital health platform uses BIS technology to measure and track critical information about the human body to aid clinicians in managing chronic disease and maximizing patient health. Its SFB7 measures fluid status and tissue composition for clinical and research applications. It offers ImpediVET, a single-channel, tetrapolar BIS device that measures fluid status and tissue composition for veterinary applications from laboratory research to clinic. SOZO applications include L-Dex Analysis for Lymphedema, BodyComp Analysis, Segmental BodyComp analysis, and HF-Dex analysis for heart failure.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.09 AUD
Average target price
0.176 AUD
Spread / Average Target
+95.58%
Consensus